Keithly Garnett
Known title: CFOCIK: 0001997371
Keithly Garnett's purchase track record
How the stock did after each of Keithly Garnett's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 4 since April 15, 2025
Stock higher 6 months later
67%
3 months: 0%
Median 6-month return
+44.0%
3 months: -26.3%
Beat the S&P 500
67%
median +20.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/14/2026 | NTHI | $1K | pending | pending | — |
| 5/22/2025 | NTHI | $5K | -21.3% | -19.1% | +11.9% |
| 5/13/2025 | NTHI | $2K | -26.3% | +54.9% | +16.3% |
| 4/15/2025 | NTHI | $2K | -45.5% | +44.0% | +23.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NTHI | ▼ Sell | Open Market | 5,000 | $17K | 9/15/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 257 | $1K | 9/14/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 675 | $5K | 5/22/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 135 | $976 | 5/19/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 90 | $631 | 5/13/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 300 | $2K | 4/15/2025 | View on chart |
| NTHI | ▼ Sell | Other | 687 | — | 3/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.